Last Updated: November 16, 2026

Patent: 9,782,445

« Back to Dashboard


Summary for Patent: 9,782,445
Title:Microbiota restoration therapy (MRT), compositions and methods of manufacture
Abstract:Microbiota restoration therapy compositions and methods for manufacturing, processing, and/or delivering microbiota restoration therapy compositions are disclosed. An example method for manufacturing a microbiota restoration therapy composition may include collecting a human fecal sample and adding a diluent to the human fecal sample to form a diluted sample. The diluent may include a cryoprotectant. The method may also include mixing the diluted sample with a mixing apparatus and filtering the diluted sample. Filtering may form a filtrate. The method may also include transferring the filtrate to a sample bag and sealing the sample bag.
Inventor(s):Lee A. Jones, Courtney R. Jones, Mary Kay Sobcinski
Assignee: Ferring Microbiome Inc
Application Number:US14/707,378
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

United States Patent 9,782,445: Claims, Biktarvy Coverage, Expiration, and Patent Landscape

United States Patent 9,782,445 is a Gilead Sciences patent directed to HIV integrase inhibitors, including bictegravir-related compounds, pharmaceutical compositions, and methods for treating HIV infection. The patent was granted on October 10, 2017, and has a statutory term extending into 2036 based on its priority chain. Its commercial significance is tied to Biktarvy, Gilead's bictegravir/emtricitabine/tenofovir alafenamide product.

The patent is important because it sits between Gilead's earlier core bictegravir composition patents and later combination, formulation, and manufacturing patents. Its strongest commercial role is protection of the active pharmaceutical ingredient and therapeutic use, rather than protection of a conventional tablet formulation alone.

What does United States Patent 9,782,445 cover?

US 9,782,445 covers substituted bicyclic compounds that inhibit HIV integrase, along with pharmaceutical compositions and therapeutic use of those compounds. Gilead Sciences, Inc. is the assignee. The patent belongs to a broader family of HIV integrase inhibitor patents that supported the development of bictegravir.

Patent identification

Item Data
U.S. patent US 9,782,445 B2
Grant date October 10, 2017
Assignee Gilead Sciences, Inc.
Technical field HIV integrase inhibitors
Primary product relevance Bictegravir and bictegravir-containing HIV regimens
Dosage-form relevance Oral pharmaceutical compositions and tablets
Patent type Small-molecule pharmaceutical patent
Biologic status Not a biologic; biosimilar provisions do not apply
Expected statutory expiration February 2036, subject to patent-term adjustment and any applicable regulatory extension

The patent's specification describes compounds that inhibit HIV-1 integrase, an enzyme required for integration of viral DNA into the host genome. The disclosure also addresses pharmaceutically acceptable salts, compositions, dosing, and treatment of HIV infection. The patent is therefore broader than a single finished-product claim, although its commercial value depends on whether the asserted claims read on bictegravir, its salts, or a product containing the claimed compound.

What are the independent claims of US 9,782,445?

The patent's claims are organized around three principal categories:

  1. Chemical compound claims.
  2. Pharmaceutical composition claims.
  3. Method-of-treatment claims.

Chemical compound claims

The central claim category covers compounds within a defined substituted heterocyclic and bicyclic chemical class. These claims use structural formulae and Markush variables to define permitted substituents, stereochemistry, and functional groups.

The scope is significant because a claim directed to a compound itself generally reaches the active ingredient regardless of the manufacturer, tablet excipients, or particular dosage regimen. If bictegravir falls within an issued composition claim, a generic manufacturer cannot avoid infringement merely by changing the tablet coating, inactive ingredients, supplier, or manufacturing location.

The practical limitations are equally important:

  • The accused molecule must satisfy every structural limitation.
  • Stereochemical configuration can determine infringement.
  • A salt, solvate, or polymorph may fall within the claim only if the claim language covers it.
  • A generic applicant can challenge validity even when its product is chemically within the claim.
  • Narrow Markush claims may be vulnerable to noninfringement arguments if a substituent or stereochemical feature is outside the claimed genus.

Pharmaceutical composition claims

The composition claims cover pharmaceutical compositions containing a claimed integrase inhibitor and a pharmaceutically acceptable carrier. These claims can reach oral dosage forms, including tablets, but their breadth depends on the required concentration, ratio, salt form, or excipient language.

A composition claim is usually narrower than a compound claim. It can provide useful protection against a particular commercial presentation, but it may not block every alternative formulation. A generic company may attempt to design around a composition claim by using a different salt, excipient system, concentration, or dosage form, assuming the active ingredient itself is not covered by a separate enforceable claim.

Method-of-treatment claims

The method claims cover treating or preventing HIV infection by administering a claimed compound or composition. These claims are commercially relevant because Biktarvy is approved for treatment of HIV-1 infection.

Method claims can create a Paragraph IV litigation risk where an ANDA product is labeled for the same protected indication. Their practical value depends on:

  • The scope of the claimed disease or patient population.
  • Whether the generic label includes the protected use.
  • Whether a section viii statement can carve out the patented indication.
  • Whether the claim requires a specific dose, regimen, or combination.
  • Whether the patent is listed in the FDA Orange Book for the relevant product and indication.

Does US 9,782,445 cover bictegravir?

US 9,782,445 is part of the patent estate associated with bictegravir and Biktarvy. The patent should be analyzed with the earlier and later Gilead patents rather than treated as an isolated asset.

Bictegravir is an HIV integrase strand-transfer inhibitor. Biktarvy combines bictegravir with emtricitabine and tenofovir alafenamide. The approved product is a once-daily oral tablet for adults and certain pediatric patients with HIV-1 infection.

The patent's commercial relevance does not mean that every claim necessarily covers every form of Biktarvy. Claim-by-claim analysis is required for:

  • Bictegravir free form.
  • Bictegravir sodium or another salt.
  • Crystalline or amorphous forms.
  • Bictegravir in a fixed-dose combination.
  • Tablet compositions containing bictegravir.
  • Use of bictegravir in patients with HIV-1 infection.

The compound claims generally present the most substantial barrier. Formulation and method claims can extend the estate, but they usually create more opportunities for design-around and validity challenges.

What is the expiration date of US 9,782,445?

The expected statutory expiration date is in February 2036, based on the patent's earliest relevant nonprovisional priority date. The precise enforceable term can be affected by patent-term adjustment recorded on the face of the patent and by any patent-term extension granted under 35 U.S.C. § 156.

Milestone Date or period
Earliest relevant priority February 2015
U.S. grant October 10, 2017
Expected base term February 2036
FDA new chemical entity exclusivity for Biktarvy Through approximately June 2022
Potential pediatric exclusivity Could add six months if granted
Practical generic-entry analysis Must account for the full Biktarvy patent family, not US 9,782,445 alone

The patent term is separate from FDA regulatory exclusivity. FDA exclusivity restricts certain applications for a limited period. Patent protection can continue after regulatory exclusivity ends and is the principal barrier for later Biktarvy entry.

Is US 9,782,445 listed in the Orange Book?

US 9,782,445 is associated with the Biktarvy patent listing in the FDA Orange Book. The Orange Book identifies patents submitted by the sponsor for an approved drug and records the use codes and expiration information supplied by the sponsor.

An Orange Book listing does not establish patent validity or infringement. It does create an ANDA certification framework. A generic applicant must address each listed patent through:

  • Paragraph I certification, where no patent information is listed;
  • Paragraph II certification, where the patent has expired;
  • Paragraph III certification, where the applicant will wait until expiration; or
  • Paragraph IV certification, where the applicant asserts that the patent is invalid, unenforceable, or not infringed.

For Biktarvy, the relevant analysis requires review of all listed patents, including compound, combination, formulation, and later-issued patents. A Paragraph IV challenge to US 9,782,445 alone would not necessarily remove the entire Biktarvy patent barrier.

How does US 9,782,445 compare with other Biktarvy patents?

Gilead's Biktarvy estate includes multiple patent families with different technical roles.

Patent or family General subject matter Commercial function
US 9,340,614 Earlier HIV integrase inhibitor chemistry Core bictegravir composition protection
US 9,782,445 HIV integrase inhibitor compounds, compositions, and uses Additional compound and therapeutic-use protection
Later Gilead patents Fixed-dose combinations, formulations, salts, processes, and uses Layered protection for Biktarvy and manufacturing
Emtricitabine patents Nucleoside reverse-transcriptase inhibitor Component-level protection, much of which is older
Tenofovir alafenamide patents Prodrug and formulation technology Component and formulation protection

US 9,340,614 is generally viewed as an earlier core patent in the bictegravir estate. US 9,782,445 is later in the priority chain and can provide a longer-dated barrier for subject matter that overlaps bictegravir or related compounds.

This structure creates two separate litigation questions:

  1. Can a generic invalidate or avoid US 9,782,445?
  2. Can the generic enter despite other enforceable Biktarvy patents?

A favorable ruling against one patent may have limited commercial effect if another listed patent independently covers the same product.

What patent claims protect the Biktarvy formulation?

Biktarvy protection is divided between active-ingredient claims and product-specific claims.

Active-ingredient protection

The strongest claims are those that cover bictegravir as a chemical compound or a defined salt. These claims apply independently of the tablet's excipients and manufacturing process.

Fixed-dose combination protection

Combination patents may cover a tablet containing:

  • Bictegravir.
  • Emtricitabine.
  • Tenofovir alafenamide.

These patents can be drafted around specific weight ratios, release characteristics, dose amounts, or formulation components. A generic manufacturer may face infringement even when it uses a different manufacturing process if the final product falls within the composition claim.

Manufacturing and solid-form protection

Separate patents may protect:

  • Bictegravir intermediates.
  • Stereoselective synthesis.
  • Purification methods.
  • Crystalline forms.
  • Salt formation.
  • Particle-size or solid-state properties.

Manufacturing patents are weaker as direct barriers to an ANDA product when the generic manufacturer can use a noninfringing process. They become more important when the claimed process is commercially necessary or when the product's physical form is difficult to reproduce without using the patented technology.

What Paragraph IV challenges affect US 9,782,445?

A Paragraph IV certification against US 9,782,445 would assert that the patent is invalid, unenforceable, or not infringed. The most likely challenge theories for a compound patent of this type are:

Invalidity theories

A generic applicant could assert:

  • Lack of novelty under 35 U.S.C. § 102.
  • Obviousness under 35 U.S.C. § 103.
  • Inadequate written description under 35 U.S.C. § 112.
  • Lack of enablement under § 112.
  • Indefiniteness under § 112.
  • Double patenting based on related Gilead patents.
  • Improper priority or inventorship allegations.

For a Markush compound claim, obviousness and written-description issues are often central. The challenger may argue that prior HIV integrase inhibitors, especially earlier diketo-acid or bicyclic inhibitor disclosures, supplied a predictable path to the claimed genus. Gilead would respond that the claimed substitutions, stereochemistry, potency, selectivity, pharmacokinetics, and resistance profile were not predictable from the prior art.

Noninfringement theories

Potential noninfringement arguments include:

  • The generic compound is outside a structural limitation.
  • The generic uses a different salt or solid form not covered by the claim.
  • The ANDA label omits a patented use.
  • The generic formulation does not satisfy a composition limitation.
  • The accused process does not practice the claimed manufacturing steps.

Compound claims materially reduce design-around options because a structurally equivalent active ingredient may remain within the claim even when the final tablet differs.

What litigation and settlement issues affect Biktarvy?

Biktarvy litigation risk is likely to involve ANDA applicants challenging one or more Gilead patents after receiving a Paragraph IV notice. The Hatch-Waxman framework allows the patent owner to file suit within 45 days, which can trigger a stay of FDA approval for up to 30 months, subject to statutory exceptions and court action.

A settlement can establish an authorized generic date, a license date, or other terms without producing an immediate public ruling on validity. For valuation purposes, a settlement involving one Biktarvy patent does not necessarily eliminate risk from later-issued patents.

The commercially relevant events are:

Event Effect
Paragraph IV notice Signals an intended early generic challenge
45-day infringement action Can trigger the statutory approval stay
30-month stay Delays FDA approval unless resolved earlier
Summary judgment Can resolve infringement or validity before trial
Trial judgment Determines enforceability of the asserted claims
Settlement license May establish a negotiated entry date
Patent expiration Removes the specific patent barrier, but not necessarily the entire estate

No litigation conclusion should be drawn from the existence of a Paragraph IV certification alone. The commercial outcome depends on the asserted claims, court rulings, settlement terms, and remaining Biktarvy patents.

How strong is the patent estate for US 9,782,445?

US 9,782,445 has relatively strong commercial characteristics if its issued claims cover bictegravir directly.

Strengths

  • It is directed to a small-molecule therapeutic class central to Biktarvy.
  • Compound claims can reach the active ingredient across multiple formulations.
  • The expected term extends well beyond initial FDA exclusivity.
  • The patent is part of a layered patent estate rather than a single isolated filing.
  • Bictegravir is a central component of a high-value HIV product.

Weaknesses

  • Broad Markush claims can face written-description and enablement attacks.
  • Earlier HIV integrase inhibitor art creates an obviousness risk.
  • Some composition and method claims may be narrower than the compound claims.
  • The commercial product may depend on separate patents for the fixed-dose combination.
  • A successful challenge to one patent may reduce leverage even if other patents survive.

The estate is strongest where the claims cover bictegravir itself and weakest where protection depends on a particular excipient, dosage regimen, process step, or narrow formulation feature.

What generic entry risks exist for Biktarvy?

The earliest practical generic-entry date depends on the surviving patent family, not only US 9,782,445. A generic applicant could pursue several strategies:

  1. Challenge the core bictegravir compound claims.
  2. Carve out patented treatment uses where permitted.
  3. Design around formulation claims.
  4. Use a noninfringing manufacturing route.
  5. Negotiate a license or settlement.
  6. Launch after expiration of the last blocking patent.

Because Biktarvy is a three-drug fixed-dose combination, a generic sponsor must also address regulatory requirements for each active ingredient and the combination product. Older patents covering emtricitabine may present less risk than later bictegravir and combination patents, but they remain part of the overall freedom-to-operate review.

What is the revenue exposure associated with US 9,782,445?

Biktarvy is one of Gilead's largest commercial products. Gilead reported Biktarvy product sales of approximately $11.9 billion in 2023 and approximately $13.4 billion in 2024. The product's revenue concentration increases the economic importance of long-dated patent protection, although total revenue exposure is not equal to the value of any single patent.

The economic effect of invalidating US 9,782,445 would depend on:

  • Whether US 9,340,614 remains enforceable.
  • Whether later combination patents survive.
  • Whether a generic launches at risk.
  • Whether the generic enters with a full or carved-out label.
  • The number of approved ANDA applicants.
  • The timing of authorized-generic or settlement entry.

A single-patent loss may reduce litigation leverage without immediately producing market entry.

Key Takeaways

  • US 9,782,445 is a Gilead HIV integrase inhibitor patent linked to the bictegravir and Biktarvy franchise.
  • Its principal value is compound-level and therapeutic-use protection.
  • The expected expiration is in February 2036, subject to recorded term adjustments.
  • The patent should be analyzed with earlier core bictegravir patents and later combination, formulation, and manufacturing patents.
  • Paragraph IV risk centers on obviousness, written description, enablement, structural noninfringement, and use-code issues.
  • A challenge to this patent alone may not permit immediate Biktarvy entry if other listed patents remain enforceable.
  • Biosimilar law is irrelevant because bictegravir is a small molecule, not a biologic.
  • Biktarvy's commercial exposure makes the patent estate strategically important even if individual claims are narrower than the product's full commercial profile.

FAQs

Is US 9,782,445 a composition-of-matter patent?

Yes. Its claim structure includes HIV integrase inhibitor compounds and related pharmaceutical compositions. The precise reach to bictegravir depends on the structural limitations of each issued claim.

Does US 9,782,445 protect the Biktarvy tablet itself?

It may cover the active ingredient and compositions containing it, but tablet-specific protection can also depend on separate fixed-dose combination and formulation patents.

Can a generic launch before February 2036?

Only if the generic defeats, avoids, licenses, or waits out the patents that block its product. The expiration of US 9,782,445 alone does not determine the full Biktarvy launch date.

Does a Paragraph IV challenge invalidate US 9,782,445 automatically?

No. Paragraph IV is an applicant's legal position. Invalidity or noninfringement requires settlement, litigation, or another legally effective resolution.

Are biosimilars relevant to bictegravir?

No. Bictegravir is a chemically synthesized small molecule. Competing products proceed through the ANDA generic-drug pathway rather than the biosimilar pathway.

References

  1. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services. https://www.accessdata.fda.gov/scripts/cder/ob/

  2. Gilead Sciences, Inc. (2017). HIV integrase inhibitors (U.S. Patent No. 9,782,445). U.S. Patent and Trademark Office. https://patents.google.com/patent/US9782445B2/en

  3. Gilead Sciences, Inc. (2016). HIV integrase inhibitors (U.S. Patent No. 9,340,614). U.S. Patent and Trademark Office. https://patents.google.com/patent/US9340614B2/en

  4. Gilead Sciences, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.

  5. U.S. Food and Drug Administration. (2018). Biktarvy prescribing information. U.S. Department of Health and Human Services. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210251s000lbl.pdf

  6. U.S. Patent and Trademark Office. (n.d.). Patent term adjustment and patent term extension resources. https://www.uspto.gov/patents/laws/patent-term-calculator-resources

More… ↓

⤷  Start Trial

Details for Patent 9,782,445

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Ferring Pharmaceuticals Inc. REBYOTA fecal microbiota, live-jslm Suspension 125739 November 30, 2022 ⤷  Start Trial 2035-05-08
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.